Hormonal
Survodutide, a dual glucagon and GLP-1 receptor agonist, induces significant weight loss in adults with obesity without type 2 diabetes when administered as a once-weekly subcutaneous injection up-titrated to 3.6 or 6.0 mg alongside lifestyle modifications.
This treatment involves a weekly injection that mimics two natural hormones (GLP-1 and glucagon) to reduce appetite and increase energy burn. It is prescribed for adults with obesity who do not have diabetes. To maximize results, patients must follow a reduced-calorie diet and exercise regularly. The dose starts low and increases slowly to minimize stomach upset, which is a common side effect.
Participants... were randomized 1:1:1 to double-blind, once-weekly, subcutaneous injections of survodutide (up-titrated to 3.6 or 6.0 mg) or placebo for 76 weeks... Survodutide, a novel glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor dual agonist, elicited significant weight loss in a phase 2 trial...
Why this rating
This is a baseline characteristics paper for a Phase 3 trial; efficacy data is not yet reported, though prior Phase 2 data is cited.
Source
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial ( <scp>SYNCHRONIZE</scp> ™‐1)
Carel W. le Roux et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.70196
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →